Literature DB >> 12113238

ZD1839 (IRESSA): a selective EGFR-TK inhibitor.

Malcolm Ranson1, Was Mansoor, Gordon Jayson.   

Abstract

The recent development of highly selective, target-based cancer therapeutics, such as ZD1839 has resulted from a greater understanding of tumor biology. Amongst the most promising of new target-based agents are inhibitors of the epidermal growth factor receptor. ZD 1839 is a potent, selective epidermal growth factor receptor tyrosine kinase inhibitor that has demonstrated promising results in early clinical trials.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12113238     DOI： 10.1586/14737140.2.2.161

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  6 in total

1.  A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.

Authors:  Edwin M Posadas; Meghan S Liel; Virginia Kwitkowski; Lori Minasian; Andrew K Godwin; Mahrukh M Hussain; Virginia Espina; Bradford J Wood; Seth M Steinberg; Elise C Kohn
Journal:  Cancer       Date:  2007-04-01       Impact factor: 6.860

2.  Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism.

Authors:  Maria Vittoria Arcidiacono; Mario Cozzolino; Noah Spiegel; Masanori Tokumoto; Jing Yang; Yan Lu; Tetsuhiko Sato; Carlo Lomonte; Carlo Basile; Eduardo Slatopolsky; Adriana S Dusso
Journal:  J Am Soc Nephrol       Date:  2008-06-25       Impact factor: 10.121

3.  FT-IR microspectrometry reveals the variation of membrane polarizability due to epigenomic effect on epithelial ovarian cancer.

Authors:  Morris M H Hsu; Pei-Yu Huang; Yao-Chang Lee; Yuang-Chuen Fang; Michael W Y Chan; Cheng-I Lee
Journal:  Int J Mol Sci       Date:  2014-10-08       Impact factor: 5.923

4.  Calcium Regulates HCC Proliferation as well as EGFR Recycling/Degradation and Could Be a New Therapeutic Target in HCC.

Authors:  Teresa Maria Elisa Modica; Francesco Dituri; Serena Mancarella; Claudio Pisano; Isabel Fabregat; Gianluigi Giannelli
Journal:  Cancers (Basel)       Date:  2019-10-18       Impact factor: 6.639

5.  Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma.

Authors:  Y Kawaguchi; K Kono; K Mimura; F Mitsui; H Sugai; H Akaike; H Fujii
Journal:  Br J Cancer       Date:  2007-07-10       Impact factor: 7.640

6.  Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.

Authors:  J-L Fischel; P Formento; G Milano
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.